文献速递白血病造血干细胞移植与细胞治疗

异基因干细胞移植治疗非典型慢性髓性白血病:欧洲血液和骨髓移植学会慢性恶性肿瘤工作组的回顾性研究

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Br J Haematol · 2017-03-28

该回顾性研究分析了1997至2006年间在欧洲血液和骨髓移植学会(EBMT)登记接受异基因造血干细胞移植(allo-HSCT)的42例非典型慢性髓性白血病(aCML)患者,中位年龄46岁,诊断至移植中位时间7个月。移植后87%达完全缓解,5年无复发生存率36%、非复发死亡率24%、复发率40%。患者年龄和EBMT评分影响总生存,MUD移植的无复发生存高于HLA同胞移植且非复发死亡率无差异。

要点

  • 异基因造血干细胞移植可使87%的aCML患者达到完全缓解。
  • 5年无复发生存率36%,非复发死亡率24%,复发率40%。
  • 患者年龄和EBMT风险评分影响总生存,年轻且低危者最适合移植。

核心结论

  • 该研究证实异基因造血干细胞移植可使相当比例的aCML患者获得治愈,年轻且EBMT风险评分低的患者是最佳候选。

研究设计与样本

  • 回顾性研究,纳入1997至2006年间在EBMT登记接受异基因造血干细胞移植的42例aCML患者。

主要发现

  • 移植后87%的患者达到完全缓解,5年无复发生存率为36%,非复发死亡率为24%,复发率为40%。
  • 患者年龄和EBMT评分对总生存有影响。
  • MUD移植的无复发生存高于HLA同胞移植,且非复发死亡率无差异。

关键数值与推荐

  • 中位年龄46岁,诊断至移植中位时间7个月,69%的患者移植时处于首次慢性期。
  • 供者类型:HLA同胞供者64%,匹配无关供者(MUD)36%;24%采用减低强度预处理。
  • MUD移植中87%应用T细胞去除,HLA同胞移植中26%应用T细胞去除。
  • EBMT风险评分:低危45%,中危31%,高危24%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Onida F, de Wreede LC, van Biezen A, et al. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2017. PMID: 28369779. doi:10.1111/bjh.14619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。